SEARCH

SEARCH BY CITATION

References

  • 1
    Von Seidlein L, Jaffar S, Pinder M, et al. Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. J Infect Dis 1997; 176: 11131116.
  • 2
    Bunnag D, Viravan C, Looareesuwan S, Karbwang J, Harinasuta T. Clinical trial of artesunate and artemether on multidrug resistant falciparum malaria in Thailand. A preliminary report. Southeast Asian J Trop Med Public Health 1991; 22: 380385.
  • 3
    Karbwang J, Bangchang K, Thanavibul A, Back D, Bunnag D, Harinasuta T. Pharmacokinetics of mefloquine alone or in combination with artesunate. Bull World Health Organ 1994; 72: 8387.
  • 4
    White NJ. The treatment of malaria. N Engl J Med 1996; 335: 800806.
  • 5
    Lefèvre G, Thomsen MS. Clinical pharmacokinetics of artemether and lumefantrine (Riamet®). Clin Drug Invest 1999; 18: 467480.
  • 6
    Lefèvre G, Bindschedler M, Ezzet F, Schaeffer N, Meyer I, Thomsen M. Pharmacokinetic interaction trial between co-artemether and mefloquine. Eur J Pharm Sci 2000; 10: 141151.
  • 7
    Ezzet F, Mull R, Karbwang J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br J Clin Pharmacol 1998; 46: 553561.
  • 8
    Skelton-Stroud P, Mull R. The Novartis Co-artemether International Development Team. Positioning, labelling, and medical information control of co-artemether tablets (CGP 56697): a fixed novel combination of artemether and benflumetol. Med Trop 1998; 58: 77S81S.
  • 9
    White NJ. Assessments of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997; 41: 638644.
  • 10
    White NJ. Preventing antimalarial drug resistance through combinations. Drug Resistance Updates 1998; 1: 39.
  • 11
    Ambroise-Thomas P. Current data on major novel antimalaria drugs: artemisinin (qinghaosu) derivatives. Bull Acad Natl Med 1999; 183: 797800.
  • 12
    Price RN. Artemisinin drugs: novel antimalarial agents. Expert Opin Invest Drugs 2000; 9: 18151827.
  • 13
    Peters W, Robinson BL. The chemotherapy of rodent malaria. LVIII. Drug combinations to impede the selection of drug resistance, Part. 2: The new generation-artemisinin or artesunate with long-acting, blood schizontocides. Ann Trop Med Parasitol 2000; 94: 2335.
  • 14
    White NJ, Van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 1999; 37: 105125.
  • 15
    Van Agtmael M, Cheng-Qi S, Qing JX, Mull R, Van Boxtel CJ. Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int J Antimicrob Agents 1999; 12: 151158.
  • 16
    Lefèvre G, Looareesuwan S, Treeprasertsuk S, et al. A Clinical and pharmacokinetic trial of six doses of artemether–lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 2001; 64: 247256.
  • 17
    Van Agtmael M, Gupta V, Van Der Wösten TH, Rutten J-PB, Van Boxtel CJ. Grapefruit juice increases the bioavailability of artemether. Eur J Clin Pharmacol 1999; 55: 405410.
  • 18
    Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Ann Rev Pharmacol Toxicol 1998; 38: 389430.
  • 19
    Bennett JE. Antimicrobial agents: antifungal agents. In The Pharmalogical Basis of Therapeutics, 8th edn. Eds: HardmanJJG, Limbird LE, MolinoffPB, RuddonRW, Goodman Gilman A. New York: McGraw-Hill 1996, 11751190.
  • 20
    Ament PW, Paterson A. Drug interactions with the nonsedating antihistamines. Am Fam Physician 1997; 56: 223231.
  • 21
    Sadowski DC. Drug interactions with antacids. Mechanisms and clinical significance. Drug Safety 1994; 11: 395407.
  • 22
    Heinig R, Adelmann HG, Ahr G. The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine. Eur J Clin Pharmacol 1999; 55: 5760.
  • 23
    Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264: 27882790.
  • 24
    Honig PK, Wortham DC, Hull R, Zamani K, Smith JE, Cantilena LR. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 1993; 33: 12011206.
  • 25
    Honig PK, Wortham DC, Hull R, et al. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin Pharmacol Ther 1993; 53: 630636.
  • 26
    Honig PK, Wortham DC, Hull R, et al. Terfenadine–ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 15131518[Published erratum appears in JAMA 1993; 269: 2088; see comments in JAMA 1993; 269: 1550–1152].
  • 27
    Simons FE, Kesselman MS, Giddins NG, Pelech AN, Simons KJ. Astemizole-induced torsades de pointes. Lancet 1988; ii: 624.
  • 28
    Van Vugt M, Ezzet F, Nosten F, et al. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg 1999; 61: 964967.
  • 29
    Van Agtmael M, Bouchaud O, Malvy D, et al. The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travelers returning from the Tropics to the Netherlands and France. Int J Antimicrob Agents 1999; 12: 159169.
  • 30
    Kshirsagar NA, Gogtay NJ, Moorthy NS, et al. A randomized, double-blind, parallel group, comparative safety and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute, uncompliacted P. falciparum malaria in adults in India. Am J Trop Med Hyg 2000; 62: 402408.
  • 31
    Bindschedler M, Lefèvre G, Degen P, Sioufi A. Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in healthy participants. Am J Trop Med Hyg 2002; 66: 295300.
  • 32
    Bindschedler M, Lefèvre G, Ezzet F, Schaeffer N, Meyer I, Thomsen M. Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. Eur J Clin Pharmacol 2000; 56: 375381.
  • 33
    Daneshmend TK, Warnock DW, Ene MD, et al. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother 1984; 25: 13.
  • 34
    Bindschedler M, Degen P, Lu ZL, Jiao XQ, Liu GY, Fan F. Comparative bioavailability of benflumetol after administration of single oral doses of co-artemether under fed and fasted conditions to healthy subjects (abstract P-01–96). Proceedings of the Xivth International Congress for Tropical Medicine and Malaria, Nagasaki, Japan, 1722 November 1996.
  • 35
    Souppart C, Gauducheau N, Sandrenan N, Richard F. Development and validation of a high-performance liquid chromatography – mass spectrometry assay for the determination of artemether and its dihydroartemisinin metabolite in human plasma. J Chromatogr B 2002; in press.
  • 36
    Mansor SM, Navaratnam V, Yahaya N, Nair NK, Wernsdorfer WH, Degen PH. Determination of a new antimalarial drug, benflumetol, in blood plasma by reverse-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1996; 682: 321325.
  • 37
    Bazett HC. An analysis of the time relations of electrocardiograms. Heart 1920; VII: 354369.
  • 38
    Ahnve S. Correction of QT interval for heart rate: review of different formulas and the use of Bazett's formula in myocardial infarction. Am Heart J 1985; 109: 568574.
  • 39
    Siegsmund MJ, Cardarelli C, Aksentijevivh M, Sugimoto Y, Pastan I, Gottesman MM. Ketoconazole effectively reverses multidrug resistance in highly resistant KB cell. J Urol 1994; 151: 485491.
  • 40
    Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2. Eur J Pharmacol 1998; 358: 289294.
  • 41
    Kremens B, Brendel E, Bald M, Czyborra P, Michel MC. Loss of blood pressure control on withdrawal of fluoconazole during nifedipine therapy. Br J Clin Pharmacol 1999; 47: 707708.
  • 42
    Polk RE, Crouch MA, Israel DS, et al. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. Pharmacother 1999; 19: 13791384.
  • 43
    Ezzet F, Van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 2000; 44: 697704.
  • 44
    Hall SD, Thummel KE, Watkins PB, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999; 27: 161166.
  • 45
    Svensson USH, Ashton M. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol 1999; 48: 528535.
  • 46
    Van Vugt M, Wilairatana P, Gemperli B, et al. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multi-drug resistant falciparum malaria. Am J Trop Med Hyg 1999; 60: 936942.
  • 47
    Bakshi R, Hermeling-Fritz I, Gathmann I, Alteri E. An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug. Trans R Soc Trop Med Hyg 2000; 94: 419424.
  • 48
    Nosten F, Ter Kuile F, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993; 341: 10541056.
  • 49
    Coyne PE, Ajayi F, Harris J, Wiley T, Worthham D, Cantilena LR. Pharmacodynamics and pharmacokinetics of halofantrine and mefloquine (abstract PII-7). American Society for Clinical Pharmacology and Therapeutics. Clin Pharmacol Ther 1996; 59: 160.
    Direct Link: